Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ionis, Novartis Partner on Next-Gen Program Targeting Lp(a) for CV Disease | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ionis, Novartis Partner on Next-Gen Program Targeting Lp(a) for CV Disease

Ionis' new and advanced technologies will be used to create next generation compound targeting Lp(a).

By: Anthony Vecchione

Ionis Pharmaceuticals, Inc., a company involved in RNA-targeted therapy, entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies’ existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound will be a potential follow-on to pelacarsen.

Ionis will receive a $60 million upfront payment from Novartis and is eligible to earn development, regulatory and commercial milestone payments, and tiered royalties. Novartis will be solely responsible for the development, manufacturing, and potential commercialization of the next generation Lp(a) therapy.

“We are pleased to expand our productive collaboration with Novartis aimed at delivering transformative therapies to patients with elevated Lp(a) who are at high risk of cardiovascular events,” said Brett Monia, Ionis’ CEO. “This collaboration is designed to leverage Ionis’ advancing RNA-targeting platform technologies to deliver a novel Lp(a)-targeting therapy that we expect will provide industry-leading efficacy and dosing frequency.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics